|
|
Volumn 16, Issue 9, 2017, Pages 591-592
|
|
FDA OKs first in vitro route to expanded approval
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;
IVACAFTOR;
AMINOPHENOL DERIVATIVE;
CFTR PROTEIN, HUMAN;
CHLORIDE CHANNEL STIMULATING AGENT;
QUINOLONE DERIVATIVE;
CFTR GENE;
CYSTIC FIBROSIS;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG SPECIFICITY;
GENE;
GENE MUTATION;
HUMAN;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
SHORT SURVEY;
FOOD AND DRUG ADMINISTRATION;
GENETICS;
MUTATION;
ORGANIZATION AND MANAGEMENT;
PROCEDURES;
UNITED STATES;
AMINOPHENOLS;
CHLORIDE CHANNEL AGONISTS;
CYSTIC FIBROSIS;
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;
DRUG APPROVAL;
HUMANS;
MUTATION;
QUINOLONES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 85028719507
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd.2017.140 Document Type: Short Survey |
|
Times cited : (9)
|
|
References (0)
|
